Seelos Therapeutics Announces Close Of Enrollment Of Registration Directed Study Of SLS-002 For Acute Suicidal Ideation And Behavior In Adults With Major Depressive Disorder
Portfolio Pulse from Bill Haddad
Seelos Therapeutics has closed enrollment for its registration-directed study of SLS-002, a treatment for acute suicidal ideation and behavior in adults with major depressive disorder.
June 22, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seelos Therapeutics' closed enrollment for SLS-002 study may lead to potential advancements in treating acute suicidal ideation and behavior in adults with major depressive disorder.
Closing enrollment for the SLS-002 study indicates that Seelos Therapeutics is moving forward with its research. Positive results from the study could lead to increased interest in the company's stock and potential growth in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100